ID: ALA41233

Max Phase: Preclinical

Molecular Formula: C28H26N2O

Molecular Weight: 406.53

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1ccc(CC(NC(=O)C(c2ccccc2)c2ccccc2)c2ccccc2)cc1

Standard InChI:  InChI=1S/C28H26N2O/c29-25-18-16-21(17-19-25)20-26(22-10-4-1-5-11-22)30-28(31)27(23-12-6-2-7-13-23)24-14-8-3-9-15-24/h1-19,26-27H,20,29H2,(H,30,31)

Standard InChI Key:  AKYQUIAWRGDGCP-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 406.53

Molecular Weight (Monoisotopic): 406.2045

AlogP: 5.50

#Rotatable Bonds: 7

Polar Surface Area: 55.12

Molecular Species: NEUTRAL

HBA: 2

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 3

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 13.99

CX Basic pKa: 4.29

CX LogP: 5.67

CX LogD: 5.67

Aromatic Rings: 4

Heavy Atoms: 31

QED Weighted: 0.40

Np Likeness Score: -0.46

References

1. Clader JW, Berger JG, Burrier RE, Davis HR, Domalski M, Dugar S, Kogan TP, Salisbury B, Vaccaro W..  (1995)  Substituted (1,2-diarylethyl)amide acyl-CoA:cholesterol acyltransferase inhibitors: effect of polar groups on in vitro and in vivo activity.,  38  (10): [PMID:7752185] [10.1021/jm00010a004]

2. Clader JW, Berger JG, Burrier RE, Davis HR, Domalski M, Dugar S, Kogan TP, Salisbury B, Vaccaro W..  (1995)  Substituted (1,2-diarylethyl)amide acyl-CoA:cholesterol acyltransferase inhibitors: effect of polar groups on in vitro and in vivo activity.,  38  (10): [PMID:7752185] [10.1021/jm00010a004]

3. Clader JW, Berger JG, Burrier RE, Davis HR, Domalski M, Dugar S, Kogan TP, Salisbury B, Vaccaro W..  (1995)  Substituted (1,2-diarylethyl)amide acyl-CoA:cholesterol acyltransferase inhibitors: effect of polar groups on in vitro and in vivo activity.,  38  (10): [PMID:7752185] [10.1021/jm00010a004]

4. Itzhak Y, Kalir A, Weissman BA, Cohen S..  (1981)  New analgesic drugs derived from phencyclidine.,  24  (5): [PMID:7241506] [10.1021/jm00137a004]

5. Bhattacharjee P, Rutland N, Iyer MR..  (2022)  Targeting Sterol O-Acyltransferase/Acyl-CoA:Cholesterol Acyltransferase (ACAT): A Perspective on Small-Molecule Inhibitors and Their Therapeutic Potential.,  65  (24.0): [PMID:36473091] [10.1021/acs.jmedchem.2c01265]

6. Bhattacharjee P, Rutland N, Iyer MR..  (2022)  Targeting Sterol O-Acyltransferase/Acyl-CoA:Cholesterol Acyltransferase (ACAT): A Perspective on Small-Molecule Inhibitors and Their Therapeutic Potential.,  65  (24.0): [PMID:36473091] [10.1021/acs.jmedchem.2c01265]

7. Bhattacharjee P, Rutland N, Iyer MR..  (2022)  Targeting Sterol O-Acyltransferase/Acyl-CoA:Cholesterol Acyltransferase (ACAT): A Perspective on Small-Molecule Inhibitors and Their Therapeutic Potential.,  65  (24.0): [PMID:36473091] [10.1021/acs.jmedchem.2c01265]

Source

Source(1):

• Scientific Literature